GW 501516 (Synonyms: GW 1516; GSK-516)

Name: GW 501516
Brand: MedChemExpress
SKU: HY-10838
Rating: 5.0 (16 reviews)

Cat. No.: HY-10838 Purity: 99.43%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

GW 501516 (GW 1516) is a PPARδ agonist with an EC₅₀ of 1.1 nM.

For research use only. We do not sell to patients.

GW 501516 Chemical Structure

CAS No. : 317318-70-0

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 85	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 204	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 286	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of GW 501516:

GW 501516 (Standard) Get quote

15 Publications Citing Use of MCE GW 501516

: GW 501516 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 28;9:648. [Abstract]; Western blot analysis of the protein expression of caspase and Bcl-2 family members in response to GW501516.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

GW 501516 (GW 1516) is a PPARδ agonist with an EC₅₀ of 1.1 nM^[1].

IC₅₀ & Target^[1]

PPARδ

1.1 nM (EC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
COS-1	EC₅₀	> 1000 nM Compound: 1, GW-501516	Agonist activity at human PPARalpha ligand binding domain expressed in COS-1 cells co-transfected with Gal4 after 24 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha ligand binding domain expressed in COS-1 cells co-transfected with Gal4 after 24 hrs by luciferase reporter gene assay	[PMID: 22051054]
COS-1	EC₅₀	0.5 nM Compound: 1, GW501516	Agonist activity at pSG5-Gal4-tagged human PPAR-beta/delta ligand binding domain expressed in COS1 cells assessed as receptor activation incubated for 19 hrs by pGL3-5XUAS-SV40 luciferase reporter gene assay Agonist activity at pSG5-Gal4-tagged human PPAR-beta/delta ligand binding domain expressed in COS1 cells assessed as receptor activation incubated for 19 hrs by pGL3-5XUAS-SV40 luciferase reporter gene assay	[PMID: 25768705]
COS-1	EC₅₀	2.9 nM Compound: 1, GW-501516	Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis Agonist activity at human PPARdelta ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis	[PMID: 22051054]
COS-1	EC₅₀	912 nM Compound: 1, GW-501516	Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells after 24 hrs by luciferase reporter gene-based luminometric analysis	[PMID: 22051054]
COS-7	EC₅₀	1 nM Compound: GW-501516	Activity at PPARbeta/delta by luciferase reporter gene transactivation assay in COS7 cells Activity at PPARbeta/delta by luciferase reporter gene transactivation assay in COS7 cells	[PMID: 16797985]
COS-7	EC₅₀	10000 nM Compound: GW-501516	Activity at PPARalpha by luciferase reporter gene transactivation assay in COS7 cells Activity at PPARalpha by luciferase reporter gene transactivation assay in COS7 cells	[PMID: 16797985]
COS-7	EC₅₀	10000 nM Compound: GW-501516	Activity at PPARgamma by luciferase reporter gene transactivation assay in COS7 cells Activity at PPARgamma by luciferase reporter gene transactivation assay in COS7 cells	[PMID: 16797985]
CV-1	EC₅₀	> 1.2 μM Compound: GW501516	Transactivation activity at human PPARgamma expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay Transactivation activity at human PPARgamma expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22534184]
CV-1	EC₅₀	0.001 μM Compound: 1, GW-501516	Agonist potency at PPARdelta in CV1 cells by cell based transient transfection assay Agonist potency at PPARdelta in CV1 cells by cell based transient transfection assay	[PMID: 17243659]
CV-1	EC₅₀	0.0012 μM Compound: GW501516	Transactivation of human PPARdelta expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of human PPARdelta expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 22579420]
CV-1	EC₅₀	0.0017 μM Compound: 1, GW-501516	Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay Agonist activity at human PPARdelta-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay	[PMID: 21515063]
CV-1	EC₅₀	0.0017 μM Compound: GW-501516	Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of Gal4-fused human PPARdelta DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 21112784]
CV-1	EC₅₀	0.99 μM Compound: 1, GW-501516	Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay Agonist activity at human PPARalpha-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay	[PMID: 21515063]
CV-1	EC₅₀	0.99 μM Compound: GW-501516	Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of Gal4-fused human PPARalpha DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 21112784]
CV-1	EC₅₀	1.888 μM Compound: 1, GW-501516	Agonist potency at PPARalpha in CV1 cells by cell based transient transfection assay Agonist potency at PPARalpha in CV1 cells by cell based transient transfection assay	[PMID: 17243659]
CV-1	EC₅₀	2.5 nM Compound: GW501516	Transactivation activity at human PPARdelta expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay Transactivation activity at human PPARdelta expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22534184]
CV-1	EC₅₀	229 nM Compound: GW501516	Transactivation activity at human PPARalpha expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay Transactivation activity at human PPARalpha expressed in african green monkey CV1 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22534184]
CV-1	EC₅₀	4.1 μM Compound: 1, GW-501516	Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay Agonist activity at human PPARgamma-LBD expressed in CV1 cells co-transfected with Gal4 after 40 hrs by luciferase based transactivation assay	[PMID: 21515063]
CV-1	EC₅₀	4.1 μM Compound: GW-501516	Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of Gal4-fused human PPARgamma DNA binding domain expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 21112784]
CV-1	EC₅₀	8.9 μM Compound: 1, GW-501516	Agonist potency at PPARgamma in CV1 cells by cell based transient transfection assay Agonist potency at PPARgamma in CV1 cells by cell based transient transfection assay	[PMID: 17243659]
HEK293	EC₅₀	> 10 μM Compound: GW-501516	Activity at human adipose tissue PPAR gamma expressed in HEK293 cells by PPAR-GAL4 transactivation assay Activity at human adipose tissue PPAR gamma expressed in HEK293 cells by PPAR-GAL4 transactivation assay	[PMID: 17343371]
HEK293	EC₅₀	0.002 μM Compound: 1, GW-501516	Agonist activity at Gal4-fused human PPARdelta DNA binding domain expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at Gal4-fused human PPARdelta DNA binding domain expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21094606]
HEK293	EC₅₀	0.0044 μM Compound: GW501516	Agonist activity at GAL4N fused human PPARdelta LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at GAL4N fused human PPARdelta LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 28539218]
HEK293	EC₅₀	0.0059 μM Compound: GW501516	Agonist activity at N-terminal Gal4 fused human PPARdelta LBD transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay Agonist activity at N-terminal Gal4 fused human PPARdelta LBD transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 27622746]
HEK293	EC₅₀	0.0059 μM Compound: GW501516	Agonist activity at GAL4-tagged human PPARdelta ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay Agonist activity at GAL4-tagged human PPARdelta ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 27591006]
HEK293	EC₅₀	0.0079 μM Compound: GW-501516	Activity at human placenta PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay Activity at human placenta PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay	[PMID: 17343371]
HEK293	EC₅₀	0.054 μM Compound: GW-501516	Agonist activity at mouse PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay Agonist activity at mouse PPAR delta expressed in HEK293 cells by PPAR-GAL4 transactivation assay	[PMID: 17343371]
HEK293	EC₅₀	0.085 μM Compound: GW-501516	Agonist activity at human PPARdelta receptor expressed in HEK293 cells by GAL4 transactivation assay Agonist activity at human PPARdelta receptor expressed in HEK293 cells by GAL4 transactivation assay	[PMID: 17524643]
HEK293	EC₅₀	0.18 nM Compound: GW501516	Agonist activity at human PPARbeta expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at human PPARbeta expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 25305688]
HEK293	EC₅₀	3.9 μM Compound: GW-501516	Activity at human liver PPAR alpha expressed in HEK293 cells by PPAR-GAL4 transactivation assay Activity at human liver PPAR alpha expressed in HEK293 cells by PPAR-GAL4 transactivation assay	[PMID: 17343371]
HeLa	EC₅₀	> 10000 nM Compound: 27, GW-501516	Agonist activity at PPARalpha ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay Agonist activity at PPARalpha ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay	[PMID: 19275963]
HeLa	EC₅₀	> 10000 nM Compound: 27, GW-501516	Agonist activity at PPARgamma ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay Agonist activity at PPARgamma ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay	[PMID: 19275963]
HeLa	EC₅₀	8 nM Compound: 27, GW-501516	Agonist activity at PPARdelta ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay Agonist activity at PPARdelta ligand binding domain expressed in human HeLa cells co-transfected with Gal4-DBD assessed as transcriptional activation by Gal4 response element-driven luciferase reporter gene assay	[PMID: 19275963]
HepG2	EC₅₀	0.0012 μM Compound: GW-501516	Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	0.8 μM Compound: GW-501516	Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	1.1 μM Compound: GW-501516	Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay	[PMID: 21215640]
HepG2	EC₅₀	4 nM Compound: GW-501516	Agonist activity at human PPARdelta in HepG2 cells by GAL4-luciferase reporter gene assay Agonist activity at human PPARdelta in HepG2 cells by GAL4-luciferase reporter gene assay	[PMID: 17512197]

In Vitro

GW 501516 is shown to be the most potent and selective PPARδ agonists known with an EC₅₀ of 1.1 nM against PPARδ and 1000-fold selectivity over the other human subtypes, PPARα and-γ^[1].
GW 501516 exerts anti-inflammatory effects in mouse cultured proximal tubular (mProx) cells. GW 501516 inhibits palmitate- and TNFα-induced increases in MCP-1 mRNA expression in a dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GW 501516 causes impaired bone formation, leading to decreased BMD and deterioration of bone properties in OVX rats^[2].
GW 501516 attenuates interstitial inflammation and proximal tubular cell damage in a protein-overload mouse nephropathy model^[3].
GW 501516 treatment enhances running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

453.50

Formula

C₂₁H₁₈F₃NO₃S₂

CAS No.

317318-70-0

Appearance

Solid

Color

White to off-white

SMILES

OC(COC1=CC=C(C=C1C)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (220.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2051 mL	11.0254 mL	22.0507 mL
5 mM	0.4410 mL	2.2051 mL	4.4101 mL
10 mM	0.2205 mL	1.1025 mL	2.2051 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.51 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.43%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (246 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8. [Content Brief]

[2]. Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155(6):2178-89. [Content Brief]

[3]. Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6(9):e25271. [Content Brief]

[4]. Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884. [Content Brief]

[5]. Ji Y, et al. PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis. Front Pharmacol. 2018 Jun 28;9:648. [Content Brief]

Cell Assay ^[3]	GW 501516 is dissolved in DMSO. Cells are starved by incubation in 0.2% FCS DMEM for 9 h, then pre-incubated with GW 501516, at a final concentration of 2.5 and 5 µM, or 0.05% DMSO as control for 3 hours, followed by stimulation with 150 µM palmitate bound to 8.0% BSA for 12 h^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]^[3]	Rats: Female Sprague Dawley rats, 12 weeks of age, are allocated to a sham-operated group and 3 OVX groups; high-dose GW 501516 (OVX-GW5), low-dose GW 501516 (OVX-GW1), and a control group (OVX-CTR), respectively. Animals receive GW 501516 or vehicle (methylcellulose) daily for 4 months by gavage. Bone mineral density (BMD) is assessed by dual x-ray absorptiometry at the femur, spine, and whole body^[2]. Mice: Mice are randomly allocated to different groups and receive therapeutic diet and treatment. The GW 501516-containing rodent diet is made by evenly adding GW 501516 to the control diet to a final concentration of 0.04% w/w. In the control diet, 10% of the total calories are from fat (5.5% from soybean oil and 4.5% from lard)^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Wei ZL, et al. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8. [Content Brief] [2]. Mosti MP, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW 501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014 Jun;155(6):2178-89. [Content Brief] [3]. Yang X, et al. GW 501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice. PLoS One. 2011;6(9):e25271. [Content Brief] [4]. Chen W, et al. A metabolomic study of the PPARδ agonist GW 501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015 May 6;5:9884. [Content Brief] [5]. Ji Y, et al. PPARβ/δ Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis. Front Pharmacol. 2018 Jun 28;9:648. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2051 mL	11.0254 mL	22.0507 mL	55.1268 mL
	5 mM	0.4410 mL	2.2051 mL	4.4101 mL	11.0254 mL
	10 mM	0.2205 mL	1.1025 mL	2.2051 mL	5.5127 mL
	15 mM	0.1470 mL	0.7350 mL	1.4700 mL	3.6751 mL
	20 mM	0.1103 mL	0.5513 mL	1.1025 mL	2.7563 mL
	25 mM	0.0882 mL	0.4410 mL	0.8820 mL	2.2051 mL
	30 mM	0.0735 mL	0.3675 mL	0.7350 mL	1.8376 mL
	40 mM	0.0551 mL	0.2756 mL	0.5513 mL	1.3782 mL
	50 mM	0.0441 mL	0.2205 mL	0.4410 mL	1.1025 mL
	60 mM	0.0368 mL	0.1838 mL	0.3675 mL	0.9188 mL
	80 mM	0.0276 mL	0.1378 mL	0.2756 mL	0.6891 mL
	100 mM	0.0221 mL	0.1103 mL	0.2205 mL	0.5513 mL

GW 501516 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GW 501516317318-70-0GW 1516 GSK-516GW501516GW-501516GW1516GW-1516GSK516GSK 516GSK-516PPARAutophagyPeroxisome proliferator-activated receptorsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

GW 501516 (Synonyms: GW 1516; GSK-516)

Customer Review

Other Forms of GW 501516:

GW 501516 Related Antibodies

15 Publications Citing Use of MCE GW 501516

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

GW 501516 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

GW 501516 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report